Adalimumab for the treatment of adults with psoriasis

TA146 Adalimumab ar gyfer soriasis: deall canllawiau NICE (fformat MS Word)

Review decision - September 2010 information

Appendix A: Decision paper presented to the Institute's Guidance Executive

Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 105 KB)

Review proposal - August 2010 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 29 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 285 KB)

NICE issues guidance on the use of adalimumab for the treatment of psoriasis in adults (PDF 29 KB)

Review decision - July 2009 information

Review proposal - October 2008 information

Provisional matrix of consultees and commentators (MSWord 67 KB)

Review decision - December 2008 information

Summary of the responses from this consultation

Psoriasis - adalimumab: final appraisal determination (FAD) information

Psoriasis - adalimumab: final appraisal determination (FAD)

Psoriasis - adalimumab: final appraisal determination (FAD) (PDF 112 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 62 KB)

Consultee and commentator comments on the ACD

Wyeth Pharmaceuticals

Wyeth Pharmaceuticals (PDF 153 KB)

Welsh Assembly Government

Welsh Assembly Government (PDF 13 KB)

Royal College of Nursing

Royal College of Nursing (PDF 20 KB)

Merck Serono

Merck Serono (PDF 283 KB)

Department of Health

Department of Health (PDF 13 KB)

British Association of Dermatologists

British Association of Dermatologists (PDF 13 KB)

Abbott Laboratories

Psoriasis - adlimumab: appraisal consultation information

Psoriasis - adalimumab: appraisal consultation document information

Psoriasis - adalimumab: appraisal consultation - pre-meeting briefing

Psoriasis - adalimumab: appraisal consultation - pre-meeting briefing (PDF 179 KB)

Psoriasis - adalimumab: appraisal consultation - Evidence Review Group report

Psoriasis - adalimumab: appraisal consultation - Evidence Review Group report (PDF 448 KB)

Psoriasis - adalimumab: appraisal consultation - Non-manufacturer submissions

British Association of Dermatologists

British Association of Dermatologists (PDF 107 KB)

Psoriasis and Psoriatic Arthritis Alliance

Psoriasis and Psoriatic Arthritis Alliance (PDF 48 KB)

Psoriasis Association

Psoriasis Association (PDF 49 KB)

Royal College of Nursing

Royal College of Nursing (PDF 15 KB)

Royal College of Physicians

Royal College of Physicians (PDF 43 KB)

Welsh Assembly Government

Welsh Assembly Government (PDF 50 KB)

Psoriasis - adalimumab: appraisal consultation - Manufacturer submission: Abbott Laboratories Ltd

Psoriasis - adalimumab: appraisal consultation - Manufacturer submission: Abbott Laboratories Ltd (PDF 1.24 MB)

Psoriasis - adalimumab: appraisal consultation - Expert written personal statements

Barker

Barker (PDF 17 KB)

Chandler

Chandler (PDF 22 KB)

Griffiths

Griffiths (PDF 18 KB)

Jobling

Psoriasis - adalimumab: Draft scope - pre-referral

Psoriasis - adalimumab: Provisional matrix of consultees and commentators - pre- referral

Psoriasis - adalimumab: Response to comments on the draft scope